Evidence map›Paper›PMID 41049849›Full record

ArticleFrontiers in oncology2025

Innovative patient-specific delivered-dose prediction for volumetric modulated arc therapy using lightweight Swin-Transformer.

Yongqiang Zhou, Changfei Gong, Junming Jian, Yun Zhang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yongqiang ZhouDepartment of Radiation and Medical Oncology, First Affiliated Hospital of Wenzhou Medical University, WenZhou Radiation Oncology and Translational Research Key Laboratory, Wenzhou, Zhejiang, China.
Changfei GongDepartment of Radiation Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China.
Junming JianDepartment of Radiation Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China.
Yun ZhangDepartment of Radiation Oncology, Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Volumetric modulated arc therapy (VMAT) necessitates rigorous pre-treatment patient-specific quality assurance (PSQA) to ensure dosimetric accuracy, yet conventional manual verification methods encounter time and labor constraints in clinical workflows. While deep learning (DL) models have advanced PSQA by automating metrics prediction, existing approaches relying on convolutional neural networks struggle to reconcile local feature extraction with global contextual awareness. This study aims to develop a novel lightweight DL framework that synergizes hierarchical spatial feature learning and computational efficiency to enhance VMAT-delivered dose (VTDose) prediction. Methods: We propose a hybrid architecture featuring a novel hierarchical fusion framework that synergizes shifted-window self-attention with adaptive local-global feature interaction. (termed "STQA"). Specially, strategic replacement of Swin-Transformer blocks with ResNet residual modules in deep layers, coupled with depthwise separable attention mechanisms, enables 40% parameter reduction while preserving spatial resolution. The model was trained on multimodal inputs and evaluated against state-of-the-art methods using structural similarity index (SSIM), mean absolute error (MAE), root mean square error (RMSE), and gamma passing rate (GPR). Results: Visual evaluation of VTDose and discrepancy maps across axial, coronal, and sagittal planes demonstrated enhanced fidelity of STQA to ground truth (GT). Quantitative analysis revealed superior performance of STQA across all evaluation metrics: SSIM=0.978, MAE=0.163, and RMSE= 0.416. GPR analysis confirmed clinical applicability, with STQA achieving 95.43%±3.41% agreement with GT (94.63%±2.84%). Conclusions: STQA establishes a paradigm for efficient and accurate VTDose prediction. Its lightweight design, validated through multi-site clinical data, addresses critical limitations in current DL-based PSQA, offering a clinically viable solution to enhance radiotherapy PSQA workflows.

Indexed as

deep learningmultimodalpre-treatment specific quality assuranceSwin-Transformervolumetric modulated arc therapy

Identifiers

PMID41049849
PMCPMC12488436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.